Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecallantide for Acute HAE Attacks (EDEMA3)
NCT00262080Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2005
- Primary completion
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing Ecallantide with Placebo (2 arms). Primary endpoint: Treatment Outcome Score at 4 Hours Post-Dose. Started Dec 2005; status: completed.
02
Drugs
ecallantide
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT00262080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262080.